Monteverde investigates Forte Biosciences sale to argenx BV at $77 a share

The law firm said it is reviewing whether the proposed all-cash deal offers fair value to Forte Biosciences shareholders.

Summary

verifying reliability

Terms & Concepts

No specialized terms available for this topic.